



Media Release

Medienmitteilung

Communiqué aux Médias

Sandoz Inc.
506 Carnegie Center
Drive, Suite 400
Princeton, NJ 08540
Phone +1 609 627 8500
Fax +1 609 627 8682
www.us.sandoz.com

Sandoz launches generic version of Elocon® lotion

Princeton, New Jersey; November 28, 2007 -- Sandoz introduced mometasone furoate, a generic equivalent of Elocon® lotion, in the U.S. recently. Mometasone furoate is used to treat various skin conditions, including dermatitis and eczema.

About Sandoz

Sandoz, a division of the Novartis group, is a global leader in the field of generic pharmaceuticals, offering a wide array of high-quality, affordable products that are no longer protected by patents. Sandoz has a portfolio of more than 840 compounds in over 5,000 forms worldwide and sells its products in more than 110 countries. Key product groups include antibiotics, treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments and hormone therapies. Sandoz develops, produces and markets these drugs along with pharmaceutical and biotechnological active substances and anti-infectives. In addition to the strong organic growth in recent years, Sandoz has made a series of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany) and Eon Labs (U.S.). In 2006, Sandoz employed approximately 21,000 people worldwide and posted sales of USD 6 billion.

Disclaimer

The foregoing release may contain forward-looking statements regarding potential additional marketing approvals or future sales of mometasone furoate. Any such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results with mometasone furoate to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that mometasone furoate will receive any additional marketing approvals in any other countries, or that it will reach any particular sales levels. Management's expectations regarding mometasone furoate could be affected by various risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sandoz is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

* * *



For further information

Sandoz US Communications:

Charles A. Bruns

609.627.8881

Elocon® is a registered trademark of Schering-Plough.